.JPG)
The Novel Drug Delivery Systems In Cancer Therapy Market Size is valued at USD 12.71 Billion in 2023 and is predicted to reach USD 63.25 Billion by the year 2031 at a 22.41 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
High-end drug delivery methods include expressing plant and bioactive extracts in microcapsules, liposomes, nano emulsions, nano capsules, hydrogels, microspheres, nanoparticles, and polymeric materials. Due to significant advantages over conventional medicines for cancer treatment, the market for novel drug delivery systems in cancer therapy is expected to grow. An increase in cancer occurrences significantly impacts the global market for novel drug delivery systems in cancer therapy. Additionally, there has been increased research activity to create novel drug delivery systems and increased financing for ongoing research initiatives.
The increase in the cost of healthcare for the detection and treatment of cancer is projected to contribute further to the expansion of the global market for novel drug delivery systems in cancer. Thus, with fresh investments and developments in the field, the high and rising burden of chronic diseases is anticipated to pave the way for developing novel drug delivery systems, and the studied market is thus expected to expand throughout the forecast period. Furthermore, the demand for novel drug delivery systems in cancer therapy is anticipated to increase due to technological developments in drug delivery systems, new investments made by private and public entities, new product launches, partnerships, and mergers and acquisitions by leading market players.
The novel drug delivery systems in the cancer therapy market are segmented based on product. Based on the product, the market is segmented into nanoparticles (liposomes, polymer, micelles, other nanoparticles) and embolization particles (PVA particles, drug-eluting beads, liquid emboli, and other embolization particles).
The nanoparticles segment is estimated to hold the largest share of the market. An innovative strategy for treating cancer uses nanoparticles as new drug delivery mechanisms. They enclose the medications and guard them against enzymatic and chemical deterioration. Long circulation half-lives, fewer adverse effects, and improved pharmacokinetics are all benefits of using nanoparticles in medication administration. Additionally, these particles have improved permeability, enabling effective medication delivery to cancer tissues.
North America region is projected to hold the largest share in the market of novel drug delivery systems in cancer therapy globally. The market is projected that the existence of various manufacturers and the availability of research funding will promote market expansion in North America or future developments in the global market for novel drug delivery systems in cancer therapy. The Asia Pacific regional market is expected to increase rapidly in the global novel drug delivery systems in cancer therapy due to the invention and introduction of technologically sophisticated drug delivery systems. Furthermore, the growing patient population with chronic diseases is predicted to propel market growth.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 10.45 Billion |
|
Revenue Forecast In 2031 |
USD 62.44 Billion |
|
Growth Rate CAGR |
CAGR of 22.25 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Teva Pharmaceutical Industries Ltd.; Johnson & Johnson Services, Inc.; GALEN; Merrimack Pharmaceuticals, Inc.; Shire; Samyang Biopharmaceuticals Corporation; Celgene Corporation; Spectrum Pharmaceuticals, Inc.; BTG. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Novel Drug Delivery Systems in Cancer Therapy Market Snapshot
Chapter 4. Global Novel Drug Delivery Systems in Cancer Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Volume (no. of units) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product Type:
5.2.1. Nanoparticles
5.2.1.1. Liposomes
5.2.1.2. Polymer
5.2.1.3. Micelles
5.2.1.4. Other nanoparticles
5.2.2. Embolization particles
5.2.2.1. PVA particles
5.2.2.2. Drug-eluting beads
5.2.2.3. Liquid emboli
5.2.2.4. Other embolization particles
Chapter 6. Novel Drug Delivery Systems in Cancer Therapy Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Novel Drug Delivery Systems in Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
6.1.2. North America Novel Drug Delivery Systems in Cancer Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
6.2. Europe
6.2.1. Europe Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2024-2031
6.2.2. Europe Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2024-2031
6.3. Asia Pacific
6.3.1. Asia Pacific Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2024-2031
6.3.2. Asia Pacific Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2024-2031
6.4. Latin America
6.4.1. Latin America Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2024-2031
6.4.2. Latin America Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2024-2031
6.5. Middle East & Africa
6.5.1. Middle East & Africa Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by Product Type, 2024-2031
6.5.2. Middle East & Africa Novel Drug Delivery Systems in Cancer Therapy Market revenue (US$ Million) by country, 2024-2031
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Teva Pharmaceutical Industries Ltd.
7.2.2. Johnson & Johnson Services, Inc.
7.2.3. GALEN; Merrimack Pharmaceuticals, Inc.
7.2.4. Shire
7.2.5. Samyang Biopharmaceuticals Corporation
7.2.6. Celgene Corporation
7.2.7. Spectrum Pharmaceuticals, Inc.
7.2.8. BTG
7.2.9. Other Prominent Players
By Product
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
